Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced that Japan's Patent Office has granted a patent covering the company's stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic, according to a press release dated September 15, 2026.

The patent, designated Japanese Patent No. 7917283, provides protection in Japan through 2039. It covers methods for predicting clinical benefit from stenoparib based on gene-expression profiles from tumor samples, as well as methods for selecting patients likely to benefit from stenoparib treatment using the DRP® test.

Thomas Jensen, Chief Executive Officer of Allarity Therapeutics, said: "Japan is one of the world's largest pharmaceutical markets and is also the home of Eisai, the original developer of stenoparib. This award reflects our ongoing strategic efforts to strengthen and extend our intellectual property, ensuring the development and potential commercialization of stenoparib—together with its DRP® companion diagnostic—in the world's most important commercial markets."

Allarity previously secured patent protection for the stenoparib DRP® in the United States, with coverage extending into April 2042, as well as in certain European jurisdictions and Australia. Related patent applications remain pending in additional international markets.

Stenoparib is an oral dual inhibitor of PARP1/2 and tankyrase 1/2 being developed for advanced ovarian cancer, among other cancer types. Allarity holds exclusive global rights to develop and commercialize the drug, which was originally developed by Eisai Co., Ltd.